Skip to main content
Erschienen in: Annals of Nuclear Medicine 8/2021

20.05.2021 | Original Article

Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab

verfasst von: Mai Kim, Wenchao Gu, Takahito Nakajima, Tetsuya Higuchi, Masaru Ogawa, Takahiro Shimizu, Takahiro Yamaguchi, Ayako Takahashi, Yoshito Tsushima, Satoshi Yokoo

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess the value of the texture analysis of fluorine-18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma (POR/M-OSCC) treated with cetuximab.

Methods

A total of 14 patients undergoing 18F-FDG-PET/CT with POR/M-OSCC were divided into the responder and non-responder groups according to cetuximab response by Response Evaluation Criteria in Solid Tumors (RECIST). The regions of interest (ROI) were set at the POR/M-OSCC lesions with the highest uptake of 18F-FDG, and the volumetric and texture features were analyzed. The features with correlation coefficient of 0.6 or more were further evaluated using the logistic regression analysis to create a model.

Results

The SHAPEVolume(vx), SHAPEVolume(mL), metabolic tumor volume (MTV), and gray-level run-length matrix run-length nonuniformity (GLRLMRLNU) were significantly different between the responder (n = 6) and non-responder (n = 8) groups (p = 0.044, 0.042, 0.047, and 0.012, respectively). The model’s area under the curve (AUC) was found to be 0.83, 0.83, 0.79, and 0.92, respectively. The heatmap with PET feature dendrogram showed four distinct clusters including them in patient’s responder and non-responder groups.

Conclusions

Higher MTV, GLRLMRLNU, SHAPEVolume(vx), and SHAPEVolume(mL) in 18F-FDG-PET images may have the prediction values for treatment response with POR/M-OSCC treated with cetuximab.
Literatur
1.
Zurück zum Zitat Adelstein D, Ml G, Pfister DG, Spencer S, Adkins D, Brizel DM, et al. Nccn guidelines insights: head and neck cancers, Version 2.2017. J Natl Compr Canc Netw. 2017;15:761–70.CrossRef Adelstein D, Ml G, Pfister DG, Spencer S, Adkins D, Brizel DM, et al. Nccn guidelines insights: head and neck cancers, Version 2.2017. J Natl Compr Canc Netw. 2017;15:761–70.CrossRef
2.
Zurück zum Zitat Wa M, Dj A. Targeting egfr in colorectal cancer. N Engl J Med. 2008;359:1834–6.CrossRef Wa M, Dj A. Targeting egfr in colorectal cancer. N Engl J Med. 2008;359:1834–6.CrossRef
3.
Zurück zum Zitat Lk L, Xy J, Xx Z, Dm W, Xl S, Hb J. Upregulation of vimentin and aberrant expression of e-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23:213–24.CrossRef Lk L, Xy J, Xx Z, Dm W, Xl S, Hb J. Upregulation of vimentin and aberrant expression of e-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23:213–24.CrossRef
4.
Zurück zum Zitat Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24.CrossRef Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24.CrossRef
5.
Zurück zum Zitat Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of P53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 1995;10:1217–27.PubMed Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of P53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 1995;10:1217–27.PubMed
6.
Zurück zum Zitat Avissar M, Mcclean MD, Kelsey KT, Marsit CJ. Microrna expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis. 2009;30:2059–63.CrossRef Avissar M, Mcclean MD, Kelsey KT, Marsit CJ. Microrna expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis. 2009;30:2059–63.CrossRef
7.
Zurück zum Zitat Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, et al. Response evaluation in head and neck oncology: definition and prediction. Orl J Otorhinolaryngol Relat Spec. 2017;79:14–23.CrossRef Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, et al. Response evaluation in head and neck oncology: definition and prediction. Orl J Otorhinolaryngol Relat Spec. 2017;79:14–23.CrossRef
8.
Zurück zum Zitat Parks SK, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013;13:611–23.CrossRef Parks SK, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013;13:611–23.CrossRef
9.
Zurück zum Zitat Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.PubMed Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.PubMed
10.
Zurück zum Zitat Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18f-fdg pet/ct imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40:133–40.CrossRef Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18f-fdg pet/ct imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40:133–40.CrossRef
11.
Zurück zum Zitat Na KJ, Choi H. Tumor metabolic features identified by 18f-fdg pet correlate with gene networks of immune cell microenvironment in head and neck cancer. J Nucl Med. 2018;59:31–7.CrossRef Na KJ, Choi H. Tumor metabolic features identified by 18f-fdg pet correlate with gene networks of immune cell microenvironment in head and neck cancer. J Nucl Med. 2018;59:31–7.CrossRef
12.
Zurück zum Zitat Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. Lifex: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.CrossRef Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. Lifex: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.CrossRef
13.
Zurück zum Zitat Kim M, Achmad A, Higuchi T, et al. Effects of intratumoral inflammatory process on 18f-fdg uptake: pathologic and comparative study with 18f-fluoro-α-methyltyrosine Pet/Ct in oral squamous cell carcinoma. J Nucl Med. 2015;56:16–21.CrossRef Kim M, Achmad A, Higuchi T, et al. Effects of intratumoral inflammatory process on 18f-fdg uptake: pathologic and comparative study with 18f-fluoro-α-methyltyrosine Pet/Ct in oral squamous cell carcinoma. J Nucl Med. 2015;56:16–21.CrossRef
14.
Zurück zum Zitat Kim M, Higuchi T, Nakajima T, Andriana P, Hirasawa H, Tokue A, et al. F-Fdg and 18f-famt pet-derived metabolic parameters predict outcome of oral squamous cell carcinoma. Oral Radiol. 2019;35:308–14.CrossRef Kim M, Higuchi T, Nakajima T, Andriana P, Hirasawa H, Tokue A, et al. F-Fdg and 18f-famt pet-derived metabolic parameters predict outcome of oral squamous cell carcinoma. Oral Radiol. 2019;35:308–14.CrossRef
15.
Zurück zum Zitat Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.CrossRef Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.CrossRef
16.
Zurück zum Zitat Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.CrossRef Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.CrossRef
17.
Zurück zum Zitat Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ. Phase Ii study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016–22.CrossRef Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ. Phase Ii study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016–22.CrossRef
18.
Zurück zum Zitat Péron J, Ceruse P, Lavergne E, Buiret G, Pham BN, Chabaud S, et al. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anticancer Drugs. 2012;23:996–1001.CrossRef Péron J, Ceruse P, Lavergne E, Buiret G, Pham BN, Chabaud S, et al. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anticancer Drugs. 2012;23:996–1001.CrossRef
19.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised recist guideline (Version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised recist guideline (Version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef
20.
Zurück zum Zitat Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao CT, Yen TC. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261–8.CrossRef Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao CT, Yen TC. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261–8.CrossRef
21.
Zurück zum Zitat Mk C, Hs J, Yi S, Yk So, Gy P, Jy C, et al. Metabolic tumor volumes by [18f]-fluorodeoxyglucose Pet/Ct correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol. 2009;16:3111–7.CrossRef Mk C, Hs J, Yi S, Yk So, Gy P, Jy C, et al. Metabolic tumor volumes by [18f]-fluorodeoxyglucose Pet/Ct correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol. 2009;16:3111–7.CrossRef
22.
Zurück zum Zitat Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18f-Fdg Pet/Ct qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853–64.CrossRef Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18f-Fdg Pet/Ct qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853–64.CrossRef
23.
Zurück zum Zitat Hj Im, Yk K, Yi K, Jj L, Ww L, Se K. Usefulness Of combined metabolic-volumetric indices of (18)F-Fdg Pet/Ct for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging. 2013;47:36–43.CrossRef Hj Im, Yk K, Yi K, Jj L, Ww L, Se K. Usefulness Of combined metabolic-volumetric indices of (18)F-Fdg Pet/Ct for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging. 2013;47:36–43.CrossRef
24.
Zurück zum Zitat Pinho DF, King B, Xi Y, Albuquerque K, Lea J, Subramaniam RM. Value of intratumoral metabolic heterogeneity and quantitative. Ajr Am J Roentgenol. 2020;214:908–16.CrossRef Pinho DF, King B, Xi Y, Albuquerque K, Lea J, Subramaniam RM. Value of intratumoral metabolic heterogeneity and quantitative. Ajr Am J Roentgenol. 2020;214:908–16.CrossRef
25.
Zurück zum Zitat Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.CrossRef Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.CrossRef
26.
Zurück zum Zitat Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.CrossRef Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.CrossRef
27.
Zurück zum Zitat Yanamoto S, Umeda M, Kioi M, Kirita T, Yamashita T, Hiratsuka H, et al. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma. Cancer Chemother Pharmacol. 2018;81:549–54.CrossRef Yanamoto S, Umeda M, Kioi M, Kirita T, Yamashita T, Hiratsuka H, et al. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma. Cancer Chemother Pharmacol. 2018;81:549–54.CrossRef
28.
Zurück zum Zitat Tsujikawa T, Rahman T, Yamamoto M, Yamada S, Tsuyoshi H, Kiyono Y, et al. F-Fdg pet radiomics approaches: comparing and clustering features in cervical cancer. Ann Nucl Med. 2017;31:678–85.CrossRef Tsujikawa T, Rahman T, Yamamoto M, Yamada S, Tsuyoshi H, Kiyono Y, et al. F-Fdg pet radiomics approaches: comparing and clustering features in cervical cancer. Ann Nucl Med. 2017;31:678–85.CrossRef
29.
Zurück zum Zitat Sf P, Ka G, Mm G, Cj S, Mm L, Sc M, et al. Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase Ib study. J Clin Oncol. 2020;38:2427–37.CrossRef Sf P, Ka G, Mm G, Cj S, Mm L, Sc M, et al. Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase Ib study. J Clin Oncol. 2020;38:2427–37.CrossRef
Metadaten
Titel
Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab
verfasst von
Mai Kim
Wenchao Gu
Takahito Nakajima
Tetsuya Higuchi
Masaru Ogawa
Takahiro Shimizu
Takahiro Yamaguchi
Ayako Takahashi
Yoshito Tsushima
Satoshi Yokoo
Publikationsdatum
20.05.2021
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 8/2021
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-021-01623-6

Weitere Artikel der Ausgabe 8/2021

Annals of Nuclear Medicine 8/2021 Zur Ausgabe